OCT 2 9 2007 W

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 10/26/07

y: Denise M. Vaillancourt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of PALIARD et al.

Serial No.: 10/643,679

Examiner: Ba

Bao Qun Li

Confirmation No.:

4593

Art Unit:

1648

Filed:

August 18, 2003

For:

ACTIVATION OF HCV-SPECIFIC T CELLS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(c)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

[X]	Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attache	æd
	Form PTO/SB/08 is enclosed.	

[]	No copies of the publications listed on the attached Form PTO/SB/08A are
	being provided pursuant to 37 C.F.R. §1.98(d) because the publications
	were previously cited by or submitted to the Office in prior Application
	Serial No to which the above-identified application claims priority
	under 35 U.S.C. §120.

Publication(s)	<u> </u>
in a foreign search	or examination report corresponding to application
serial no.	and mailed on

10/29/2007 SDENBOB3 00000019 10643679 02 FC:1806 180.00 OP

		of the l	M.P.E.F	copy of a non-English publication(s) Pursuant to §609 P., Applicant submits the attached foreign search or eport, which cites such non-English language publication(s).				
	[]		copy of a non-English publication(s) English language _ (copy enclosed) claims priority from this non-English					
	[]	Enclosed is an explanation of non-English publication(s) for English translation is not available.						
			Enclosed is an English translation of non-English publication(s) in the attached Form PTO/SB/08A.					
	[]	Enclosed is a copy of pending patent Application Serial No						
C.F.R.				closure Statement is filed after the period specified in 37 he mailing of:				
		[X]	a final	action under 37 C.F.R. § 1.113;				
[] a notic			a notic	ce of allowance under 37 C.F.R. § 1.113; or				
		[]	an acti	on that otherwise closes prosecution in this application.				
	In accordance with 37 C.F.R. § 1.97(c) also enclosed is:							
		[X]	Fee under 37 C.F.R. § 1.17(p) in the amount of \$180.00; or					
		[]	Statem	ent as specified in 37 C.F.R. § 1.97(e):				
			[]	Each item of information contained in the Information Disclosure Statement cited herein was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or				
				No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, having made a reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.				

Attorney Docket No. PP001612.0009 (2300-1612.10) Serial No.10/643,679

Page 3

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: 0 ch ha 21, 2017

Respectfully submitted,

Novartis Vaccines and Diagnostics, Inc. Intellectual Property – R440 P.O. Box 8097 Emeryville, CA 94662-8097

By:

Jenny Buchbinder Reg. No. 48,588